Peter Mattson

Peter Mattson leads the ML Performance Measurement at Google. He co-founded and is the General Chair of MLPerf. Previously, he founded the Programming Systems and Applications Group at NVIDIA Research, was VP of software infrastructure for Stream Processors Inc (SPI), and was a managing engineer at Reservoir Labs. His research focuses on accelerating and understanding the behavior of machine learning systems by applying novel benchmarks and analysis tools. Peter holds a PhD and MS from Stanford University and a BS from the University of Washington.

Sailesh Kottapalli

Sailesh Kottapalli is an Intel Senior Fellow and the chief architect of data center processor architecture in the Silicon Engineering Group. He leads a team of architects responsible for developing the architecture of Intel® Xeon® and Intel® Atom™ server product lines as well as the overall compute solutions strategy for datacenter segment. He also leads a cross-organizations effort in driving the technology leadership on the Interconnect pillar. Kottapalli joined Intel in 1996 as a design engineer working on the first Intel® Itanium® processor, then code-named “Merced.” Subsequently, he served as lead engineer for several Intel Itanium and Intel Xeon processor evaluations, and more recently, as lead architect for a series of Intel Xeon server processors. His work in this area earned Kottapalli an Intel Achievement Award for delivering record generational performance improvements in a high-end server product. An active participant in industry and internal conferences, Kottapalli has authored or co-authored several published technical papers, delivered talks and taken part in roundtables and panel discussions. He has also been granted approximately three dozen patents in processor architecture, with additional patents pending. Kottapalli holds a bachelor’s degree in computer science from Andhra University in India and a master’s degree in computer engineering from Virginia Tech.

Elena Severin

Walter Faulstroh

Jarrad Aguirre

Jarrad Aguirre, MD, MBA, is Head of Corporate Strategy and Advocacy at Myovant Sciences, a healthcare company focused on women's health and prostate cancer. In this role, he oversees corporate communications, patient advocacy, and digital strategy, and serves on the Executive Committee. 
 
Prior to joining Myovant, Jarrad worked as a physician, researcher, and consultant across the spectrum of health and healthcare, including at Brigham and Women's Hospital (a teaching hospital of Harvard Medical School), The Colorado Health Foundation, the Bill & Melinda Gates Foundation, and Collective Health. 
 
He graduated with honors from Yale University and University of Oxford, where he studied as a Rhodes Scholar. He completed the MD/MBA at Stanford University, supported by the Jack Kent Cooke Foundation Graduate Scholarship.  

Russell James

Jeffrey Erb

Jeffrey D. Erb is the President of McCann Health: Engagement, the healthcare customer engagement agency within McCann Health and part of the IPG Network. McCann Health Engagement is a leading organization across the globe, developing solutions to most effectively engage with healthcare clients through media and the use of proprietary data applications.

Prior to joining McCann Health, Mr. Erb served as the President of HealixGlobal, the healthcare specialty media agency within IPG Mediabrands, with a market presence and offices in over 100 countries. In his role, he led the organization for several consecutive years of over 50% YOY growth, more than tripled the size of the agency, and lead transformational change in the pharmaceutical media industry on a global level. For over 16 years, Jeff has been a leader in Life Sciences and Healthcare marketing and media. After launching a Pharmaceutical marketing company in 1999 which he sold to a healthcare company, he went on to help large media and marketing agencies launch or reignite their own healthcare divisions.

His experience in defining new strategies for clients in both HCP and Consumer Life Sciences marketing spans from media and analytics, to digital solutions and global pricing strategies. His work has spanned across a wide range in products and therapeutic categories.

His leadership has garnered him a Ben Franklin Award for Most Innovative New Company and he has been featured in numerous television and print news stories, including The Wall Street Journal, Philadelphia Enterpriser Magazine, TSM News, among others, and was named one of the top 100 people to watch by Philadelphia Style Magazine. Most recently he was named a 2019 Top 10 Innovation Catalyst by MM&M Magazine, one of the 2018 Pharma Elite by PM360 Magazine, a Health Influencer 50 by MM&M and received the Innovator of the Year Award from DTC Perspectives. He has also led Healix to win the 3rd Annual Humanitarian Award from Healthcare Marketer’s Exchange and to receive the 2018 Most Innovative Company Award from PM 360.

Mr. Erb has frequently spoken nationally as an expert in the fields of media, business development, and technology at events such as Internet World and the Wharton Technology and Media Conference among others. He is a member or has served on the board of numerous business and philanthropic organizations on both a local and National level, including the Medical Marketing Association, and has served as a Director of the Divine Providence Auxiliary Association for handicapped children.

On a personal note, Jeff is an avid investor and producer of feature films, a musician, and he enjoys sailing, skiing and spending time with his family.

Angie Kalousek Ebrahimi

Lynn Seely MD

Lynn Seely, MD, is the Chief Executive Officer of Myovant Sciences, a healthcare company focused on developing innovative treatments for women’s health and prostate cancer. Dr. Seely is an endocrinologist with over 20 years of drug development and executive leadership experience. Prior to Myovant, she served as Chief Medical Officer at Medivation from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies.

Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.